United States: FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar - Goodwin Procter LLP

Friday, 26 April 2024 (2 weeks ago)
On April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and Johnson's STELERA® (ustekinumab).

👓 View full article

0 shares	Share Tweet Save Post Send

Related videos from verified sources

Nvidia & darpa biohybrid

https://www.youtube.com/watch?v=0Hg7XhbXuac . No One is Talking About What Just Happened..

Credit: Rumble Duration: 55:45Published on March 29, 2024

United States: FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar - Goodwin Procter LLP

You Might Like

Related videos from verified sources